Osteoporosis
Conditions
Interventions
Group 1 :250 mL 0.9% sodium chloride solution, 15minutes for zoledronic acid
Group 1 :250 mL 0.9% sodium chloride solution, 60 minutes for zoledronic acid
Group 3:1000 mL 0.9% sodium chloride solution, 15 minutes for zoledronic acid
Group 4:1000 mL 0.9% sodium chloride solution, 60 minutes for zoledronic acid
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria of osteoporosis, that is, those who meet any of the following DXA measurements of lumbar spine 1-4 femoral neck total hip or distal radius 1/3 bone mineral density T value = 50 mL/min/1.73m2, blood Cr is within the normal reference range, and blood calcium is normal; 4. Patients voluntarily participate in this trial, and sign the consent form with informed consent to drug intervention and index measurement.
Exclusion criteria
Exclusion criteria: 1. People who are allergic to drug ingredients; 2. Combined with chronic kidney disease, diabetes, nephropathy, severe hypertension and other diseases that may affect renal function; 3. Those who have a recent history of taking nephrotoxic drugs such as aminoglycoside antibiotics, sulfonamides, and drugs containing aristolochic acid; 4. Patients clearly diagnosed as secondary OP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimation of glomerular filtration rate;Serum creatinine;Blood urea nitrogen;Cysatin C; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute phase reaction; | — |
Countries
China
Contacts
Public ContactDecai Chen
Department of Endocrinology, West China Hospital of Sichuan University
Outcome results
None listed